Q2 2025 Earnings Forecast for Blueprint Medicines Co. Issued By Zacks Research (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC) – Stock analysts at Zacks Research boosted their Q2 2025 earnings estimates for Blueprint Medicines in a research report issued to clients and investors on Wednesday, October 9th. Zacks Research analyst A. Chakraborty now forecasts that the biotechnology company will post earnings of ($0.78) per share for the quarter, up from their previous estimate of ($0.79). The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.99) per share. Zacks Research also issued estimates for Blueprint Medicines’ Q3 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.54) EPS, Q1 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.08) EPS and FY2026 earnings at $0.01 EPS.

BPMC has been the subject of several other reports. Baird R W upgraded Blueprint Medicines to a “strong-buy” rating in a report on Friday, August 2nd. Robert W. Baird boosted their price objective on shares of Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Barclays increased their price objective on shares of Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a research report on Monday, July 29th. Guggenheim lifted their target price on shares of Blueprint Medicines from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, Needham & Company LLC reissued a “buy” rating and set a $130.00 price target on shares of Blueprint Medicines in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

Blueprint Medicines Stock Up 0.6 %

BPMC stock opened at $89.18 on Monday. The stock has a market capitalization of $5.58 billion, a P/E ratio of -18.54 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65. Blueprint Medicines has a 1-year low of $43.89 and a 1-year high of $121.90. The business has a fifty day moving average price of $90.78 and a 200-day moving average price of $98.96.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.49. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The business had revenue of $138.20 million for the quarter, compared to analysts’ expectations of $104.02 million. During the same period in the prior year, the firm posted ($2.19) EPS. The firm’s quarterly revenue was up 139.9% on a year-over-year basis.

Insider Buying and Selling

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the transaction, the insider now directly owns 69,070 shares in the company, valued at $6,169,332.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Philina Lee sold 41,913 shares of Blueprint Medicines stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the sale, the insider now owns 34,729 shares of the company’s stock, valued at approximately $3,236,395.51. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Fouad Namouni sold 3,633 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the transaction, the insider now owns 69,070 shares of the company’s stock, valued at $6,169,332.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Blueprint Medicines

Several institutional investors and hedge funds have recently modified their holdings of the stock. Triad Wealth Partners LLC bought a new stake in shares of Blueprint Medicines in the second quarter worth about $27,000. Covestor Ltd grew its holdings in Blueprint Medicines by 9,700.0% during the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 291 shares in the last quarter. Headlands Technologies LLC increased its stake in Blueprint Medicines by 105.2% in the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 342 shares during the last quarter. Natixis purchased a new stake in shares of Blueprint Medicines during the 1st quarter worth approximately $73,000. Finally, CWM LLC raised its holdings in shares of Blueprint Medicines by 114.6% during the 2nd quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 590 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.